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Chapter I: Chromium in Today’s World 
The Los Angeles Times cites the hexavalent chromium as one of the most dangerous 
toxic contaminants in California’s air.1 Estimates from the Occupational Safety & Health 
Administration (OSHA) indicate that every year 380,000 U.S. industrial workers are 
exposed to hexavalent chromium on the job, mainly through inhalation. Hexavalent 
chromium, in the form of dichromate, is used in chrome plating, stainless steel welding 
and the production of chromate pigments and dyes. In these settings, chromium dust is 
released into the air where it can be inhaled by workers. The presence of these chromium 
dust particles result in the air becoming toxic in areas where many of these plants are 
present. This dangerous hexavalent molecule is also often recognized in popular culture 
as a toxic metal, partly due to the 2000 Oscar-award winning film Erin Brockovich. 
In February 2006, the Los Angeles Times reported that the chromium industry and 
their consulting scientists withheld and skewed data in an attempt to make the findings 
more favorable to industry.1 This article cites a report written by Michaels et al., 
published in Environmental Health: A Global Access Science Source, which closely 
examined the questionable activities of scientists working for the industrial consulting 
firm, ENVIRON. Both resources suggest that the unchanged data showed that workers 
exposed to any level, even low levels, of chromate were dying from lung cancer 
Chromium (VI) is classified as a human carcinogen by the National Toxicology 
Program and the International Agency for Research on Cancer, and has been documented 
as a cause for lung cancer for over fifty years. Given this knowledge, the U.S. federal 
agency that regulates the workplace—the Occupational Safety and Health Administration 
1 
(OSHA) — casually set a standard permissible exposure limit (PEL) of 52 micrograms of 
chromium per cubic meter of air for an 8-hour time-weighted average. This limit was 
based on a standard level which had been suggested in 1971. In 1993, a petition to lower 
the level of acceptable exposure was submitted to OSHA by the Oil, Chemical, and 
Atomic Workers International Union (OCAW) (which is now a part of the United 
Steelworkers).2 This request resulted in two lawsuits. Both challenged OSHA’s delay 
(which was felt to be unreasonable) in implementing a higher standard. The chromium 
industry-backed OSHA in this. On April 2, 2003 the U.S. Court of Appeals for the Third 
Circuit ordered that the final rule on the reduction of occupational exposure be decided 
by January 18, 2006. 
In 2004, OSHA suggested that the standard of 52 micrograms of chromium per 
cubic meter of air be lowered to 1 microgram. The OSHA proposal received negative 
comments from industry, despite the benefits that lower to this level would provide for 
workers health. Industry groups claimed that making this change would “bankrupt 
businesses and cost the metal-finishing industry $380 million annually.”3 Industry 
representatives also challenged the new standard with the findings of a 2002 study. 
As Michaels et al2 explain, industry consultants working for ENVIRON 
conducted a 2002 study in four separate plants, two German and two in the U.S. In the 
proposal for the study, the scientists said that they would look at the results from the four 
plants as a single group. This would give their report significance through the combined 
cohort. Upon completing the study and discovering that the combined results indicated 
elevated cancer risks at low levels of exposure, the scientists changed their tune and 
2 
submitted the data in two separate pieces, separating the plants by country. In making this 
change the scientists were able to manipulate their study in a manner that allowed for 
them to disguise the cancer rate. The separated results, which indicated no cancer link in 
the U.S. plants and elevated cancer risk in the German plants, were presented to OSHA in 
an attempt to show that the recommended strict standard was unwarranted. The results of 
this study were never published together, but instead were only published as separate 
documents. 2 The fact that both the scientists and the industry representatives were 
willing to alter results in their benefit brings forth the question of ethics and vested 
interests. Michaels et al. suggest that industry scientists were looking out more for the 
bottom line than for human health and well-being. 
During the 2004-2005 rulemaking proceedings, OSHA requested information like 
the data collected by in the ENVIRON study, yet those researchers choose once again to 
not release their information in one report .2 Instead of protecting their employees and the 
employees of other companies working with dichromate, the chromium industry chose to 
use altered results, to reduce its regulatory burden. The honesty of researchers is counted 
upon in making decisions, as “many U.S. regulatory agencies, including the EPA and the 
Food and Drug Administration (FDA) rely heavily on unpublished studies, submitted by 
study sponsors, in reaching regulatory decisions. ” 2 If consultants choose not to be 
truthful in the results they share, they hurt more people than they help financially. 
Situations like this are not unique to the chromium industry, as examples are 
found in many industrial settings. The Michaels et al. report challenged what they 
referred to as the faulty, biased handling of a cancer study by ENVIRON. Michaels, the 
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director of the Project on Scientific Knowledge and Public Policy at George Washington 
University’s School of Public Health, said in an February 2006 interview,. “This was a 
10-year campaign to shape the science to fit the industry’s agenda rather than shape the 
regulation to fit the science,” 1. In response to Michaels’ assessment, Joel Barnhart the 
vice president of technical issues at Elementis Chromium’s plant in Corpus Christi, Texas 
said, “I would categorically say there was not an orchestrated effort to hide anything. 
What I can say is that it certainly may have not been handled well. 1” His lawyerly words 
suggest that he is attempting to avoid criminal liability by suggesting that the actions 
taken were not done so in an attempt to cause harm, or deceive anyone. In stating that it 
was not “handled well,” he is suggesting that it was nothing more than an act of 
mismanagement and negligence.3 By carefully choosing his statement he makes it appear 
that there was not a criminal act committed. 
At the end of their report, Michaels et al. report recommend that: “Parties in 
regulatory proceedings should be required to disclose whether the studies they submit 
were preformed by researchers who had the right to present or publish their findings 
without the sponsor’s consent or influence.”2 This would allow the agencies to weigh the 
submitted information accordingly. 
On May 30, 2006 the new Permissible Exposure Limit (PEL) set by OSHA went into 
effect. Significantly lower than the prior PEL of 52 µg/m..4 , the new rule limits exposure 
of workers to 5 µg/m4 over an 8-hour time-weighted average. For the companies that feel 
they cannot meet this new standard OSHA requires a compliance alternative. Not only 
did the new rule significantly lower the amount of chromium that workers can be exposed 
4 
to, it also called for a number of changes for worker protection. These changes include 
requirements for “exposure determination, protective clothing and equipment, hygiene 
areas and practices, medical surveillance, record keeping, and start-up dates that include 
four years for the implementation for engineering the controls to meet the PEL.”4 
The connection between the development of illness and cancers following continuous 
related chromium (VI) exposure has been known for over 50 years.2 The best estimates of 
cancer cases due to industrial chromium exposure suggest that eight cancer cases occur 
for every one hundred workers, who have worked 40 years.4 The recent changes in PEL 
should help to lower the number of these cases, but it is likely that all the cases will not 
be eliminated. Further research into the biological details of chromium cancers is needed, 
as well as enforcement of the new allowable exposure levels. 
5 
Chapter II: Chemistry of Chromium: an Introduction into the Nature,

Biological Role, and Toxicity of Chromium

Chromium is a biologically important metal that is commonly found in II, III, and 
VI oxidation states, although transients states, such as IV and V also exist. Chromium II 
is strongly reducing and is easily susceptible to air oxidation. As detailed in chapter one, 
two of these states, VI and III, are known within popular culture, due to news coverage 
and the film Erin Brockovich. Chromium (III) will be discussed further, as it is an 
important as a dietary supplement in metabolism. 
Chromium (VI) — now recognized as a hazardous, carcinogenic— can only be 
understood clearly through further studies of chromium’s various oxidation states. Cr 
(VI), as well as Cr (III) are known to be the products of the disproportionation of both 
transient species, chromium IV and V. Chromium (V), as an intermediate of chromium 
(VI), has been suggested to be a major player in chromium related cancers. 
Glucose Tolerance Factor and Chromium (III) 
Trivalent chromium is the most stable oxidation state of chromium and has the 
largest number of known coordination compounds. It is an essential part of human and 
animal diets. Chromium (III) is known to be an essential co-factor in the metabolism of 
glucose and is the active component of the glucose tolerance factor (GTF). 5 The GTF 
plays a role in binding insulin to receptor sites on membranes. Although this form of 
chromium is essential to the body in small amounts, large amounts can be harmful and 
potentially fatal. 5 Although, many aspects of the GTF have yet to be bio-chemically 
6 
defined, it has been suggested that the GTF plays an important role in insulin activity, but 
this too remains undefined. 6 
Chromium Toxicity 
Hexavalent chromium is a known carcinogen when ingested in large amounts. Cr 
(VI) is easily ingested by workers in industrial settings, through inhalation or contact. 
People have also been exposed to Cr (VI) through contaminated food and water.5 It is a 
well-established cause for human lung cancer and is potentially widespread due to its 
solubility in water. 
Exposure to chromium (VI) primarly occurs in industrial settings. The 
predominate chromium compound used in the chrome-industry is sodium dichromate 
(Na2Cr2O7). At a physiological pH of pH 7, this chromium compound becomes CrO42-, 
which is the form that often enters cells through the sulfate transport channel 6. This 
system is an anion channel that allows for sulfate to pass into the cell. This entry becomes 
possible because the molecule that usually passes through this system is SO42-, which is 
comparable to CrO42- in size and charge. The sulfate transport channel provides the 
opportunity for chromium molecules to enter the cells and mitochondria of a number of 
cells in mammals. Insoluble chromium compounds, which cannot use the anion channels, 
enter the cell through phagocytosis.7 Upon entering the cell, Cr (VI) can cause direct 
DNA damage. Upon its entering the cells the chromate is reduced by glutathione, 
ascorbic acid, or cysteine. 6 The intracellular reduction of Cr (VI) to Cr (III) forms 
reactive Cr (V), Cr (IV), along with other free radical intermediates, all of which are 
capable of causing DNA damage. Stabilization of Cr (V) and Cr (VI) within the cells can 
also occur, with glutathione and ascorbate being the most likely cellular reductants.7 
7 
The tripeptide, glutathione (GSH), is found in concentrations up to 10mM

intracellularly, and is an essential antioxidant within the body. GSH is found within and 
outside of the cells and is homeostatically controlled, with its highest concentrations 
found in the liver. Its functions include involvement in catalysis, metabolism, transport, 
and detoxification8. The interaction between chromium and glutathione in the body is 
central to being able to understand chromium toxicity, as has been indicated by a number 
of past experiments. One such experiment looked at the effect on chromium toxicity in 
chick embryo hepatocytes when GSH was induced into the cells. The results of the study 
indicated that GSH played an important role, as the total number of DNA strand breaks 
was found to increase in the cells where the GSH had been added.9 
Although Cr (VI) is a known human bronchial carcinogen, its mechanism of 
action is not clearly understood.10 Cr (VI) is often reduced by glutathione within the 
body, creating free-radicals or other reaction species including Cr (V). Many previous 
studies have suggested that the Cr (V) intermediates, formed from interactions between 
Cr (VI) and GSH, play a direct (and major) role in DNA cleavage.11 
As will be discussed, the present research was focused on gaining further 
understanding of the disproportionation and reactivity of synthesized chromium (V)­
glutathione molecule in a laboratory setting. The importance of the interaction between 
chromium and glutathione within the body are known and has been studied, but the 
details of the chemistry still remain unclear, with many unanswered questions. The Cr 
(V)-GSH complex is not likely to be formed in large quantities in vivo,12 as the reduction 
of Cr (VI) with GSH in the presence of D-glucose or other 1,2-diolatoligands 
predominantly result in the formation of Cr (V)-carbohydrate complexes.7 Nonetheless, 
8 
the Cr (V)-GSH is formed initially during Cr (VI) intercellular reduction and are 
important potential sources of reactive species that should be examined. 
9

Chapter III: Chemistry of Chromium (V): 
Structure and Reactivity of Chromium (V) –Glutathione Complex 
Hexavalent chromium is a potential carcinogen and an occupational hazard in 
industries (for example, chrome dye, welding and leather tanning ). Higher levels of 
chromium (VI) are responsible for chromium dermatitis, although every oxidation state 
of chromium is known to be able to react with nucleic acids and proteins. Chromates 
enter into the cells via the sulfate transport channel and are reduced to genotoxic 
chromium (V) by a large number of intracellular reductants, such as citrate, lactate, 
ascorbate, hydrogen peroxide, and glutathione. 
Ligand exchange reactions are a prerequisite for electron transfer in the oxidation 
of organic substrates by chromium (V). As chromium (V) has been identified to be the 
ultimate carcinogen or the primary species acting in chromium related cancers, ligand 
exchange studies at the chromium (V) center are critical to the understanding of 
chromium genotoxicity. 
The tripeptide glutathione (GSH, γ-Glu-Cys-Gly, LH5, Figure 1)) is found both 
inside and around cells, in concentrations up to 10 mM intracellularly, with the highest in 
the liver. Glutathione exists in the body in two forms: the reduced form, or antioxidant, 
which is used in this study, and in the oxidized form known as glutathione disulfide. In 
the body, GSH has functions during catalysis, metabolism, amino acid transport, and 
detoxification. GSH is the central molecule in the body’s antioxidant system. As the 
antioxidant system is the body’s premier source of protection against free radicals and 
other oxidative stressors, understanding the reaction that occurs between 
10 
Cr (V) and GSH to the essential in understanding chromium genotoxicity. 14 
Figure 1: Structure of GSH 
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Since Rocek and colleages discovered bis [2-ethyl-2-hydroxybutanoato (2-) 
oxochromate (V), [CrVO(ehba) 2]- (Figure 2, 1a) and bis [2-hydroxy-2­
methylbutanoato(2-) oxochromate (V), [CrVO (hmba) 2] – (Figure 2, 1b), 15 these 
complexes have served as model systems for studies of the structure and reactivity of Cr 
(V) complexes, as well as the mechanism of chromium genotoxicity and chromium-
induced cancer. However, the above chromium (V) models have several limitations. As 
neither ehba (2-ethyl-2-hydroxybutanoic acid) nor hmba (2-hydroxy-2-methylbutanoic 
acid) is thought to have any cytosolic or mitochondrial biochemistry, their ability to cause 
in vitro DNA damage may not be physiologically relevant. 
Figure 2: Structure of Chromium (V) complexes with ehba and hmba 
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In the most comprehensive structural study of the chromium (V) –glutathione 
complex to date, the green chromium (V)-GSH complex was shown to involve thiolato 
11 
IV
and amido (deprotonated) bonding to the Cr (V) center. The assigned structure (Figure 
3) is consistent with EPR, ES-MS, XAFS and XANES data. 7 
Figure 3: Structure of Cr (V)-GSH 
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The present investigation is concerned with a detailed study of the decomposition 
of the green Cr (V) complex as a function of the ligand concentration, pH and buffer 
concentration. The Cr (V)-citrate complex, [CrVO(caH2)2]-, first reported by Regis 
University students, 16 and the relatively stable [CrVO(ehba)2], 7 have been studied as a 
point of comparison for the Cr (V)-GSH complex. 
Materials and Methods 
The known chromium (V) complexes with ehba and hmba were prepared 
according to the literature methods that can be found in Krumpolc et al.. 7 The chromium 
(V)-GSH complex was synthesized as follows: 7.7g of glutathione (25 mmol) was 
dissolved in 15 ml of deionized (D.I.) water and titrated to pH 7.0 using 3 M NaOH and 
brought to a total volume 25 mL using D.I. water. An aqueous solution of sodium 
chromate (2.5 mmol) was then made by dissolving 0.410 g in 25mL of D.I. water. The 
12 
GSH solution was mixed with aqueous sodium chromate solution. The reaction mixture 
was allowed to stand for 3 minutes. A total of 100 mL of ice cold MeOH was added to 
the solution. Some precipitate was noted immediately. The reaction mixture was then 
stored in a deep freeze for 48 hours. The resulting green complex was then collected by 
suction filtration, dried and stored in a dessicator at 4oC. A Cr (V)-citrate complex was 
also made according to published methods.16 
The structure and reactivity of these chromium (V) compounds have been studied 
through the use of EPR, mass Spectra and UV-Vis-spectroscopy. 
EPR Studies 
X-band EPR spectra of ligand-exchange reactions and solid-state EPR spectra 
were run on a Varian E9 spectrometer. One mm melting point capillary tubes were used 
for solution spectra, while solid-state EPR spectra were determined using quartz tubes. 
The magnetic field modulation frequency was 100 KHz. The uncertainty in g values is 
about +/- 0.0005. The Cr (V) content of the samples is quantified by comparing the 
normalized EPR double integral to that of a gravimeterally prepared solution of tempone 
(Aldrich Chemical, 99%). Ligand exchange reactions initiated by dissolving the 
complexes in different buffers were examined. 
Spectrophotometric Studies 
A Beckman DU-600 UV-visible spectrophotometer equipped with thermostatted 
cuvette holders was used to study the complexes. Kinetic studies of the Cr (V)-GSH 
complex decomposition at neutral pH in a 0.1 M phosphate buffer (pH 7.00; 0.1 M total 
phosphate; ionic strength (0.22) was monitored for evidence of decomposition at both 
372 nm and 610 nm. 
13 
Sulfhydryl Studies 
The total sulfhydryl groups in the Cr (V)-GSH complex was determined using 
Ellman’s reagent and a modified version of Ellman's method described in Sedlak and 
Lindsay 17 . Ellman's method is based on the reduction of 5,5'-dithiobis-(2-nitobenzoic 
acid) (DTNB, Ellman’s reagent) by SH groups, which forms 1.0 mole of 2-nitro-5­
mercaptobenzoic acid per mole of SH. The reaction is shown below: 
NO2 R S S NO2 
COOH R SH 
NO2 
S 
COOH 
S 
HS NO2 COOH 
COOH 
The 2-nitro-5-mercaptobenzoic acid has an intensive yellow color which can be used to 
measure SH concentration using UV-Vis spectroscopy.18, 19 
Two standard calibration curves were created, one using DL-cyteine and one 
using GSH. Standard 2.0 * 10-4 M solutions of DL-cysteine and GSH were made using 
0.02 M EDTA (the GSH solution was first bubbled in nitrogen), from which aliquots 
were taken to obtain the desired concentrations (from 1*10-6 M to 9*10-6 M in 10 mL 
total volume) within the reaction solutions. All solutions were maintained at a pH of 8.0 
or above. The reaction mixtures were made in 15.0 mL test tubes containing 1.5 mL of 
0.2 M Tris Buffer pH 8.2, 0.1 mL of 0.01 M DTNB (in MeOH), and a combination of 
2.0 * 10-4 M stock solution of [Cys] or [GSH] and 0.02 M EDTA totaling 0.5 mL. These 
were added to achieve the desired concentration of Cys or GSH in a 10 mL sample. The 
14 
mixture was then brought to 10.0 mL using 7.9 mL of methanol (MeOH). The tubes were 
then covered and allowed to react for 30 minutes. The absorbance of each solution was 
then taken at 412 nm in 1 cm cuvettes. The pH of the reaction mixture was maintained at 
a minimum of pH of 8.0 through the readings to allow for optimal color. 
Two sets of reaction mixtures were made at varying concentrations of Cr (V)­
GSH. The first set was made according to the following procedure, with the volume of 
0.02 M EDTA and aliquiot of Cr (V)-GSH stock solution used, varying according to 
desired concentration, and always totaling 500 µL. 
A typical solution preparation: A reaction mixture containing 
7.0 * 10-6 M Cr (V)-GSH 
1.5 mL of 0.2 M Tris Buffer (pH 8.2), 0.1 mL of 0.01 M DTNB and 150 µL of 0.02 M EDTA 
were added to a 15 mL test tube. The 2.0 * 10-4 M stock solution ofCr (V)-GSH was then 
prepared, bubbled. A 350 µL aliquiot of Cr (V)-GSH stock solution was then placed in the test 
tube containing the reaction mixture. The solution was then brought to a total volume of 10 mL 
using MeOH. The color was then allowed to develop for 30 minutes. 
The second set was prepared without the use of Ellman’s reagent, replacing it with 0.1 
mL MeOH to maintain the total volume of 10 mL. The second mixture was observed at 
372 nm, to allow for the detection of the Cr (VI) species in the solution. 
Results and Discussion 
The EPR signal of the Cr (V)-GSH complex was essentially lost within the time 
of mixing and transfers into the EPR cavity. The green complex (Figure 3) was relatively 
more stable in deoxygenated solutions containing 10-50 mM of glutathione (pH 6.8-7.0). 
At 50 mM GSH, the dominant EPR signal has a g value equal to 1.986, while in 10 mM 
15 
GSH, two Cr (V) signals were observed. In addition to the g = 1.984 signal, a second, 
sharp Cr (V) species (minor) was observed (g =1.993) (Figure 4). 
Figure 4: X-Band EPR Spectra Cr (V)-Glutathione Complex in pH 6.8 GSH 
Buffer (50mM) 
Both the Cr (V) species rapidly decayed within 10 minutes of dissolution in 
aqueous GSH solutions. In aqueous solution (pH 6-8), the green complex showed two 
well-defined and relatively stable EPR signals (g = 1.984 and 1.993; Figure 2). The 
green complex was relatively more stable in deoxygenated solutions containing 10-50 
mM of glutathione (pH = 6.8 –7.0). Kinetics of the decay of chromium (V) were 
followed by collecting 7-8 spectra during a 10 minute period. First order rate constants 
were estimated from the ln (height of the EPR signal or the normalized integrals) versus 
time plots. As the disproportionation reaction of chromium (V) 
3 Cr(V) → 2 Cr(VI) + Cr(III) 
could have a potential second-order dependence on Cr (V), second order kinetic plots 
were obtained by plotting [1/heightof EPR signal] versus time. The first order plots 
(Figure 5) were consistently better (Correlation coefficient of 0.9945) than the second 
order plots (Figure 6). 
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When the Cr (V)-GSH complex was dissolved in ehba buffer (0.1M, pH 3.5), the Cr (V)­
GSH signal was lost within the time of mixing (2 minutes) and a new stable signal 
appeared at g =1.976 which is characteristic of the [CrVO(ehba)2]- complex (Figure 7). 
[CrVO(GSH)2]4- + 2ehba → [CrVO(ehba)2]- + GSH ­
17 
Figure 7: X-Band EPR Spectra Cr (V)-Glutathione Complex in

pH 3.5 EHBA Buffer (0.1 M)

In a typical experiment using a 25 mM solution of Cr (V)-GSH, approximately 
1.15 mM (a typical calculation is shown below) [CrVO(ehba)2]- was quantified. This 
means that the decomposition of Cr (V)-GSH is faster than the ligand exchange with 
ehba. It is interesting to note that in the work of Levina, et al 7, there was a near 
stoichiometeric ligand exchange with ehba (50% [CrVO(ehba)2]-and 50% Cr (III)). 
Interestingly, it was observed that the reaction mixture (resulting from ligand exchange) 
in the EPR capillary tube is more stable than reaction mixture left outside. It may well be 
due to some oxygen involvement, which merits further investigation. 
A typical calculation is shown below.

Normalized integral for Tempone / 1.25mM =

Normalized integral for [CrVO(ehba)2]-/ X concentration

The decomposition of Cr (V) may involve competing disproportionation and 
ligand oxidation 
3 Cr (V) → 2 Cr (VI) + Cr (III) 
18 
In order to determine the mechanism of Cr (V) decomposition versus ligand 
exchange, we studied the kinetics of the decomposition reaction by Uv-Vis. Spectroscopy 
(630 nm). Even though the kinetic fits were equally satisfactory for first-order (plot of 
log A630nm versus time) (Figure 8) and second-order (1/A630nm versus time) (Figure 9), 
the decomposition reactions became increasingly faster at higher initial concentration, 
pointing to a second order pathway. 
Figure 8: First Order Plot of Cr (V) decay monitored at 610 nm 
[42 mM Cr(V)-GSH in pH 7.00 Phosphate Buffer (0.1 M)] 
Figure 9: Second Order Plot of Cr (V) Decay Monitored at 610 nm

[42 mM Cr(V)-GSH in pH 7.00 Phosphate Buffer (0.1 M)]

19 
The calibration curves for DL-cysteine (Figure 10) and GSH (Figure 11) both

proved to be fairly linear with R2 values of 0.9957 and 0.9853. 
Figure 10: Calibration Curve for Varying Concentrations of DL-cystiene using Ellman's Reagent 
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Figure 11: Calibration Curve for Varying Concentrations of GSH using Ellman's Reagent 
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A sample of the absorbance readings taken for varying concentrations of Cr (V)­
GSH are outlined in Figure 12. Using the equation of the line from the GSH calibration 
curve (y = 0.1393x + 0.0306), the concentration of GSH within the reaction mixtures was 
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determined using the absorbencies taken at 412 nm. The concentration of GSH within the 
solutions is outlined in Figure 12. 
Figure 12: Calculated GSH and Cr (VI) Concentrations 
Concentration of 
Cr(V)-GSH in 
Starting Solution 
Absorbance at 412 
nm 
(Ellman’s Reagent 
Present) 
Concentration 
of GSH 
Absorbance at 
372 nm 
(no Ellman’s 
Reagent) 
Concentration of 
Cr(VI) * 
7 X 10-6 M 0.2799 1.79 X 10-6 M 0.0349 7.27083 X 10-7M 
5 X 10-6 M 0.1649 9.64 X 10-7M 0.0201 4.1875 X 10-7M 
3 X 10-6 M 0.1597 9.27 X 10-7M 0.0158 3.29167 X 10-7 M 
1 X 10-6 M 0.0649 2.46 X 10-7M 0.0078 1.625 X 10-7 M 
*Concentration of Cr (VI) was calculated using Beer- Lambert Law and an Extinction 
Coefficient of 4.8 * 104 M-1 cm -1 at 372 nm 
Since there are two GSH molecules for every one Cr (V) molecule in the starting Cr (V)­
GSH complex (Figure 3), if complete disproportionation was occurring the concentration 
of GSH would be anticipated to be twice that of the starting Cr (V)-GSH concentration. 
As can be seen in Figure 12, this was not the finding of our experiment. Instead, the 
studies revealed the presence of only 9-15% the expected concentration of GSH. This 
finding suggests that majority of the GSH is being converted to the disulfide, GSSH, 
prior to the readings. The Cr (VI) present as a result of disproportionation was 
comparable with that found for GSH, with 12-24% of the expected Cr (VI). 
When comparing the concentration of GSH determined to be in each solution with 
the concentration of Cr (VI) in the same starting concentration of reaction mixture, a 
relationship of 1.5 to 2.8 moles of GSH for every 1.0 mole of Cr (VI) was found. This 
finding is somewhat consistent with that of previous studies which found that there was 
2.0 moles of GSH for every 1.0 mole of Cr (VI). 7 
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In the recent work of Lay et al, the decomposition kinetics (monitored at 630 
nm) of the green chromium (V) complex in water could be fitted to two consecutive first-
order processes. Interestingly, the decomposition of oxochromium (V) complexes of 
hydroxyl-carboxylic acids15 is second order in chromium (V), consistent with the 
disproportionation reaction: 
3Cr (V) � 2Cr (VI) + Cr (III) 
In our work, both EPR and UV-Vis. kinetics of decomposition of the Cr (V)-GSH 
complex (in pH 7 phosphate buffer) could not unequivocally establish first-order and 
second order pathways. As in the pH range 8.0-8.5, disproportionation of chromium (V) 
is the dominant pathway; we are presently investigating the decomposition kinetics. 
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Afterward: A Reflection on My Time Spent with Chromium 
As I look back over the last few years of research, I realize that the time that I 
spent working with Dr. Mahapatro and other research students has given me the 
opportunity to experience science as a part of life. I have come to understand the 
importance of persistence, collaboration and community. 
In the beginning working independently seemed like a very scary idea. I felt like I 
was going to mess things up, as I had never previously had the opportunity to do 
laboratory-type work without supervision. In high school we completed experiments in 
our various science classes, like chemistry, but always under the close watch of a teacher. 
I was not confident in my ability to make wise decisions in an independent situation. 
But, to my surprise, being pushed to work in this manner taught me more than I would 
have learned otherwise. Instead of being lost and clueless, I searched for answers and 
procedures. For example, I remember having a procedure question on a day when Dr. 
Mahapatro was out of town and needing an immediate answer. My first instinct was to 
give up and go home for the day, but instead I decided to search for the answer to my 
question and found it in one of my textbooks. 
I gained more than just lab experience working with Dr. Mahapatro and the other 
research students. That time allowed me to develop a comfort zone on campus that I may 
have not have found otherwise, as I never lived on campus. It also allowed me to make 
close friends, with whom I came to understand that in science (and the world), we 
encounter numerous failures for every single success. This lesson came after we 
conducted a variety of various experiments within laboratory class and research settings; 
some which were finished very quickly, and others which required two or three hours, or 
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even an entire days time. All of these experiments were conducted with a goal in mind, 
like synthesizing a molecule, and time devoted, just to discover that nothing came of the 
time spent. This is the point where we were faced with the question of whether to quit, or 
start over, or try again. It is at these moments (and there were many) that I asked myself 
why I was doing the work in the first place; was it worth it? And it was during one of 
these more recent moments that I realized it was worth it. Whether I got useable results or 
not, I have gained so much from this trial and error process. In this work I have gained 
confidence in my ability to search for answers and to work as an individual within a very 
interdependent world. This process of trial and error taught me the importance of 
persistence, which is an important life lesson. 
The interplay of independence and interdependence within the scientific 
community is not something that I came to understand easily. Working independently 
within a lab setting is important, but I always felt comfort in knowing that I was never 
truly working alone. In an undergraduate setting research often begins by building on the 
previous work of others, attempting to answer new questions or to clarify topics and 
understanding, as was the case in with my research. Specifically, our research team at 
Regis built on the previous work of O’Brien et al.12, and Levina et al.7 Through 
publishing, conferences, and interpersonal communication, different perspectives and 
ideas are shared within the larger community to come to some answers over time. 
Second, I have experienced how most scientific understanding is not completed in 
one place, but is done in pieces and stages, which are later combined to come to a final 
understanding. In the case of research on Chromium V, we collaborated with Drs. Sandra 
and Gareth Eaton of the University of Denver. Our collaboration extends further than our 
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use of their equipment (EPR)., to to the combination of ideas and answering of questions. 
We have often come to points where we have questions that we could not answer, but 
perhaps someone else could. 
Having recently attended the annual American Chemical Society conference in 
Chicago, I have had the chance to see the community of scholars in action. At first the 
conference was a little overwhelming with its large program book, variety of event 
venues (some things took place at the conference center, while others were held at the 
many ACS hotels), and an interesting shuttle schedule. But once I figured out which 
events I wanted to attend, and what set of shuttles I could use to get there, I was much 
more comfortable. With a number of talks all occurring at once it was sometimes difficult 
to decide which to attend, but I found that the various talks and workshops organized 
specifically for undergrad students provided me the opportunity to watch as ideas and 
work were shared. The undergraduate section of the conference was organized in a way 
that allowed for the students to become acquainted with the Chemical community, while 
learning information that could be useful to them in the future should they chose to move 
on to graduate school. During the poster session I overheard a conversation between two 
University professors who were discussing how the conference experience is valuable for 
students, and that this is something that they want to share with their respective 
administrations. They stressed that conferences give students the opportunity to meet 
other students with similar interests and to network with other people within the chemical 
community who may be important to them later in their career. 
Ultimately the question is why does all of this matter? All the time I spent 
participating in undergraduate research at Regis and working with Dr. Mahapatro has 
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given me a number of opportunities that I may not have otherwise encountered. So, 
ultimately, for me, it comes down to the importance of undergraduate research. I feel that 
it is important for schools to offer programs like this, which allow students to develop an 
understanding of independence and persistence within an encouraging environment. For 
me, the encouragement and support that I have found through the research and thesis 
process has allowed for me to grow both as academically and personally. 
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